• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

心力衰竭伴射血分数降低患者植入式心脏除颤器早期死亡的预测因素。

Predictors for early mortality in patients with implantable cardiac defibrillator for heart failure with reduced ejection fraction.

机构信息

Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.

Department of Cardiology, Sultan II. Abdülhamid Han Training and Research Hospital, Istanbul, Turkey.

出版信息

Indian Heart J. 2022 Mar-Apr;74(2):127-130. doi: 10.1016/j.ihj.2022.01.003. Epub 2022 Jan 31.

DOI:10.1016/j.ihj.2022.01.003
PMID:35104458
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9039682/
Abstract

Implantable cardioverter defibrillators (ICD) are recommended in heart failure with reduced ejection fraction (HFrEF) patients to reduce arrhythmic deaths. This study aimed to identify risk factors associated with mortality within one-year following the ICD. The data from our hospital's electronic database system was extracted for patients who were implanted ICD secondary to HFrEF between 2009 and 2019. Overall, 1107 patients were included in the present analysis. Mortality rate at one-year following the device implantation was 4.7%. In multivariate analysis; age, atrial fibrillation, New York Heart Association classification >2, blood urea nitrogen, pro-brain natriuretic peptide and albumin independently predicted one year mortality.

摘要

植入式心脏复律除颤器（ICD）被推荐用于射血分数降低的心力衰竭（HFrEF）患者，以降低心律失常性死亡。本研究旨在确定与 ICD 植入后一年内死亡率相关的危险因素。从我们医院的电子数据库系统中提取了 2009 年至 2019 年因 HFrEF 植入 ICD 的患者的数据。共有 1107 例患者纳入本分析。装置植入后一年的死亡率为 4.7%。多变量分析中；年龄、心房颤动、纽约心脏协会分级>2、血尿素氮、脑利钠肽前体和白蛋白独立预测一年死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5adc/9039682/a6bebc836ef4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5adc/9039682/a6bebc836ef4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5adc/9039682/a6bebc836ef4/gr1.jpg

相似文献

1
Predictors for early mortality in patients with implantable cardiac defibrillator for heart failure with reduced ejection fraction.心力衰竭伴射血分数降低患者植入式心脏除颤器早期死亡的预测因素。
Indian Heart J. 2022 Mar-Apr;74(2):127-130. doi: 10.1016/j.ihj.2022.01.003. Epub 2022 Jan 31.
2
Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality.射血分数降低的心力衰竭患者中一级预防植入式心脏复律除颤器使用的预测因素：心脏性猝死和全因死亡率预测风险的影响
Eur J Heart Fail. 2022 Jul;24(7):1212-1222. doi: 10.1002/ejhf.2530. Epub 2022 May 22.
3
Kidney dysfunction and deterioration of ejection fraction pose independent risk factors for mortality in implantable cardioverter-defibrillator recipients for primary prevention.肾功能障碍和射血分数恶化是植入式心脏复律除颤器一级预防患者死亡的独立危险因素。
Clin Cardiol. 2012 Sep;35(9):575-9. doi: 10.1002/clc.22018. Epub 2012 Jun 15.
4
Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.植入式心脏复律除颤器在糖尿病伴射血分数降低心力衰竭患者中的疗效。
Clin Res Cardiol. 2019 Aug;108(8):868-877. doi: 10.1007/s00392-019-01415-z. Epub 2019 Jan 28.
5
Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction.心力衰竭且射血分数降低患者植入式心脏复律除颤器植入用于心脏性猝死一级预防的患者障碍。
Singapore Med J. 2016 Apr;57(4):182-7. doi: 10.11622/smedj.2016072.
6
Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.植入式心脏复律除颤器患者特定病因死亡率的竞争风险分析：EVADEF队列研究。
Am Heart J. 2009 Feb;157(2):391-397.e1. doi: 10.1016/j.ahj.2008.09.023. Epub 2008 Dec 3.
7
One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System.退伍军人事务部医疗系统内植入式心脏复律除颤器植入后的一年死亡率。
Eur J Heart Fail. 2020 May;22(5):859-867. doi: 10.1002/ejhf.1755. Epub 2020 Feb 28.
8
Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial.UNTOUCHED 试验：在射血分数较低的原发性预防患者中使用 S-ICD 的主要结果。
Circulation. 2021 Jan 5;143(1):7-17. doi: 10.1161/CIRCULATIONAHA.120.048728. Epub 2020 Oct 19.
9
Vectorcardiography Findings Are Associated with Recurrent Ventricular Arrhythmias and Mortality in Patients with Heart Failure Treated with Implantable Cardioverter-Defibrillator Device.向量心电图检查结果与心力衰竭患者植入式心脏复律除颤器治疗后复发性室性心律失常和死亡率相关。
Cardiology. 2020;145(12):784-794. doi: 10.1159/000509766. Epub 2020 Sep 21.
10
Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.可穿戴式心脏复律除颤器支持的强化心力衰竭治疗优化以避免过早植入植入式心脏复律除颤器——PROLONG研究
J Am Heart Assoc. 2017 Jan 17;6(1):e004512. doi: 10.1161/JAHA.116.004512.

引用本文的文献

1
Multimorbidity in Incident Heart Failure: Characterisation and Impact on 1-Year Outcomes.新发心力衰竭中的共病：特征及其对1年预后的影响。
J Clin Med. 2024 Jul 8;13(13):3979. doi: 10.3390/jcm13133979.

本文引用的文献

1
Prospective evaluation of outcome of Indian patients who meet MADIT II (Multicenter Automatic Defibrillator Implantation Trial) criteria for implantable cardioverter defibrillator implantation: is it appropriate for Indian patients?前瞻性评估符合 MADIT II（多中心自动除颤器植入试验）植入式心脏复律除颤器植入标准的印度患者的结局：是否适合印度患者？
Indian Heart J. 2020 May-Jun;72(3):172-178. doi: 10.1016/j.ihj.2020.05.018. Epub 2020 Jun 18.
2
Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.SCD-HeFT 中植入式心脏复律除颤器治疗的长期结果。
J Am Coll Cardiol. 2020 Jul 28;76(4):405-415. doi: 10.1016/j.jacc.2020.05.061.
3
One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System.
退伍军人事务部医疗系统内植入式心脏复律除颤器植入后的一年死亡率。
Eur J Heart Fail. 2020 May;22(5):859-867. doi: 10.1002/ejhf.1755. Epub 2020 Feb 28.
4
Developing a risk score to predict mortality in the first year after implantable cardioverter defibrillator implantation: Data from the Israeli ICD Registry.开发一种风险评分模型以预测植入式心脏复律除颤器植入后一年内的死亡率：来自以色列 ICD 登记处的数据。
J Cardiovasc Electrophysiol. 2018 Nov;29(11):1540-1547. doi: 10.1111/jce.13725. Epub 2018 Sep 25.
5
Cardiac cachexia in sub-Saharan Africa.撒哈拉以南非洲地区的心脏恶病质
Indian Heart J. 2017 Nov-Dec;69(6):784-787. doi: 10.1016/j.ihj.2017.08.022. Epub 2017 Aug 30.
6
Persistent high blood urea nitrogen level is associated with increased risk of cardiovascular events in patients with acute heart failure.持续的高血尿素氮水平与急性心力衰竭患者心血管事件风险增加相关。
ESC Heart Fail. 2017 Nov;4(4):545-553. doi: 10.1002/ehf2.12188. Epub 2017 Jun 27.
7
Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey.印度心房颤动的心血管风险概况与管理：来自RealiseAF调查的真实世界数据。
Indian Heart J. 2016 Sep-Oct;68(5):663-670. doi: 10.1016/j.ihj.2015.12.011. Epub 2016 Feb 28.
8
Comorbidity of atrial fibrillation and heart failure.心房颤动与心力衰竭的并存。
Nat Rev Cardiol. 2016 Mar;13(3):131-47. doi: 10.1038/nrcardio.2015.191. Epub 2015 Dec 10.
9
Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.住院心力衰竭病情恶化患者血尿素氮的预后价值：来自血管加压素拮抗剂在慢性心力衰竭中的急性和慢性治疗影响（ACTIV in CHF）研究的见解
J Card Fail. 2007 Jun;13(5):360-4. doi: 10.1016/j.cardfail.2007.02.005.
10
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.加拿大植入式除颤器研究（CIDS）：植入式心脏复律除颤器与胺碘酮的随机试验。
Circulation. 2000 Mar 21;101(11):1297-302. doi: 10.1161/01.cir.101.11.1297.